Evidence mapPaperPMID 40180913Full record

ArticleNature communications2025

Inhibiting acute, axonal DLK palmitoylation is neuroprotective and avoids deleterious effects of cell-wide DLK inhibition.

Xiaotian Zhang, Heykyeong Jeong, Jingwen Niu, Sabrina M Holland, Brittany N Rotanz, John Gordon, Margret B Einarson, Wayne E Childers, Gareth M Thomas

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Xiaotian ZhangCenter for Neural Development and Repair, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, USA.
Heykyeong JeongCenter for Neural Development and Repair, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, USA.
Jingwen NiuCenter for Neural Development and Repair, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, USA.
Sabrina M HollandCenter for Neural Development and Repair, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, USA.
Brittany N RotanzCenter for Neural Development and Repair, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, USA.
John GordonMoulder Center for Drug Discovery, School of Pharmacy, Temple University, Philadelphia, PA, USA.
Margret B EinarsonMolecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Wayne E ChildersMoulder Center for Drug Discovery, School of Pharmacy, Temple University, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-0527-3684
Gareth M ThomasCenter for Neural Development and Repair, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 19140, USA. gareth.thomas@temple.edu.ORCID http://orcid.org/0000-0003-3183-8431

Funding

WORD PROCESSING CENTER--COREP30CA006927 · RESEARCH INST OF FOX CHASE CAN CTR · 1985 to 2025
$48.9M
Regulation of Axonal Signaling by PalmitoylationR01NS094402 · TEMPLE UNIV OF THE COMMONWEALTH · 2025 to 2025
$396k
BrightFocus Foundation (BrightFocus) G2019267NCI NIH HHS P30 CA006927NCI NIH HHS R50 CA211479NEI NIH HHS R21 EY029386NINDS NIH HHS R01 NS094402Shriners Hospitals for Children #85190 PHIShriners Hospitals for Children #87400
6 · The paper itself

Abstract

Inhibiting dual leucine-zipper kinase (DLK) could potentially ameliorate diverse neuropathological conditions, but a direct inhibitor of DLK's kinase domain caused unintended side effects in human patients, indicative of neuronal cytoskeletal disruption. We sought a more precise intervention and show here that axon-to-soma pro-degenerative signaling requires acute, axonal palmitoylation of DLK. To identify potential modulators of this modification, we screened >28,000 compounds using a high-content imaging readout of DLK's palmitoylation-dependent subcellular localization. Several hits alter DLK localization in non-neuronal cells, reduce DLK retrograde signaling and protect cultured dorsal root ganglion neurons from neurodegeneration. Mechanistically, the two most neuroprotective compounds selectively prevent DLK's stimulus-dependent palmitoylation and subsequent recruitment to axonal vesicles, but do not affect palmitoylation of other axonal proteins assessed and avoid the cytoskeletal disruption associated with direct DLK inhibition. Our hit compounds also reduce pro-degenerative retrograde signaling in vivo, revealing a previously unrecognized neuroprotective strategy.

Indexed as

AxonsLipoylationNeuroprotective AgentsProtein Kinase InhibitorsAnimalsCells, CulturedGanglia, SpinalHumansMAP Kinase Kinase KinasesMiceMice, Inbred C57BLNeuronsRatsSignal TransductionMAP Kinase Kinase Kinasesmitogen-activated protein kinase kinase kinase 12Neuroprotective AgentsProtein Kinase Inhibitors

Identifiers

PMID40180913
PMCPMC11968826

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.